药明海德苏州基地获巴西ANVISA GMP认证

DoNews
Feb 13

2026年2月13日,药明海德宣布其苏州生物制剂灌装厂(DP17)通过巴西国家卫生监督管理局(ANVISA)GMP认证。该认证专用于布坦坦研究所登革热疫苗(Butantan-DV)的本地化生产项目。认证地点为江苏苏州,主体为药明海德苏州基地,事件为获得ANVISA针对特定疫苗产品的GMP许可。此举旨在支持该疫苗在巴西及拉美市场的临床供应与商业化准备,标志着中国CDMO企业首次为巴西本土疫苗项目提供...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10